Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A study co-led by the University of Oxford and University of Birmingham, published in Lancet Oncology today by the UK Coronavirus Cancer Monitoring Project (UKCCMP), found that blood cancer patients were particularly at risk with 57% higher odds of severe disease if they contract COVID-19. This was when compared to other cancer patients, such as breast cancer, which was shown to have the lowest risk overall.

coronavirus cell © Alissa Eckert, MS; Dan Higgins, MAM

In line with what we already know about the coronavirus pandemic, age was shown to play a factor in the overall outcome, with cancer patients over the age of 80 found to have the highest frequency of fatality. As access to treatment remains of upmost importance, this information will help clinicians to guide patients to ensure they can have therapy safely and successfully during this time.

When COVID-19 spread globally in early 2020, cancer patients were identified as a sub-group who were potentially at an increased risk of infection of COVID-19 and of potentially suffering more serious disease consequences. It was this concern that led to the formation of the national UKCCMP project.

As cancer treatments need to carry on during the pandemic, this study gives clinicians and patients important information to make informed decisions about that treatment. The production of risk tables for different cancer types will let doctors discuss the risks and benefits with patients, so that together they can pick the best way to treat each person’s cancer. The study also gives an evidence base from which hospitals and other healthcare providers can design measures to ensure that they maintain access to life-saving treatments as safely as possible.

The full story is available on the Cancer Research UK Oxford centre website

This story is also featured on the University of Oxford website

Similar stories

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.